CHARLOTTE C SUN to Cystadenocarcinoma, Serous
This is a "connection" page, showing publications CHARLOTTE C SUN has written about Cystadenocarcinoma, Serous.
Connection Strength
3.063
-
Contemporary primary treatment of women with stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC): Determinants of relapse and disease-free survival. Gynecol Oncol. 2022 11; 167(2):139-145.
Score: 0.611
-
Endocrine therapy in the management of low-grade serous ovarian/peritoneal carcinoma: Mounting evidence for therelative efficacy of tamoxifen and aromatase inhibitors. Gynecol Oncol. 2020 12; 159(3):601-603.
Score: 0.533
-
Impact of Age and Primary Disease Site on Outcome in Women With Low-Grade Serous Carcinoma of the Ovary or Peritoneum: Results of a Large Single-Institution Registry of a Rare Tumor. J Clin Oncol. 2015 Aug 20; 33(24):2675-82.
Score: 0.371
-
The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes. Gynecol Oncol. 2022 06; 165(3):560-567.
Score: 0.148
-
The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance. Gynecol Oncol. 2020 09; 158(3):653-658.
Score: 0.131
-
Low-grade serous ovarian cancer: State of the science. Gynecol Oncol. 2020 03; 156(3):715-725.
Score: 0.127
-
Impact of lympho-vascular space invasion on tumor characteristics and survival outcome of women with low-grade serous ovarian carcinoma. J Surg Oncol. 2018 Feb; 117(2):236-244.
Score: 0.107
-
The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer. Gynecol Oncol. 2015 Jan; 136(1):25-9.
Score: 0.088
-
Acceptability of prophylactic salpingectomy with delayed oophorectomy as risk-reducing surgery among BRCA mutation carriers. Gynecol Oncol. 2014 May; 133(2):283-6.
Score: 0.084
-
KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma. J Pathol. 2013 Dec; 231(4):449-56.
Score: 0.083
-
Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol. 2012 Jun; 125(3):661-6.
Score: 0.074
-
Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube. Gynecol Oncol. 2012 Jun; 125(3):640-5.
Score: 0.073
-
Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study. Cancer. 2012 Jun 15; 118(12):3087-94.
Score: 0.072
-
Low-grade serous primary peritoneal carcinoma. Gynecol Oncol. 2011 Jun 01; 121(3):482-6.
Score: 0.069
-
Clinicodemographic factors influencing outcomes in patients with low-grade serous ovarian carcinoma. Cancer. 2011 Aug 15; 117(16):3741-9.
Score: 0.068
-
Is low-grade serous ovarian cancer part of the tumor spectrum of hereditary breast and ovarian cancer? Gynecol Oncol. 2011 Feb; 120(2):229-32.
Score: 0.067
-
BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas. Am J Pathol. 2010 Oct; 177(4):1611-7.
Score: 0.066
-
Preventing future cancers by testing women with ovarian cancer for BRCA mutations. J Clin Oncol. 2010 Feb 01; 28(4):675-82.
Score: 0.062
-
Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol. 2009 Jul; 114(1):48-52.
Score: 0.060
-
Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol. 2008 Mar; 108(3):510-4.
Score: 0.055
-
Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma. Gynecol Oncol. 2007 Jun; 105(3):625-9.
Score: 0.052
-
The BRK tyrosine kinase is expressed in high-grade serous carcinoma of the ovary. Cancer Biol Ther. 2006 Sep; 5(9):1136-41.
Score: 0.050
-
Does tamoxifen use affect prognosis in breast cancer patients who develop endometrial cancer? Obstet Gynecol. 2004 Aug; 104(2):255-60.
Score: 0.011